Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound.
Nakano, H., Saito, N., Parker, L.J., Tada, Y., Abe, M., Tsuganezawa, K., Yokoyama, S., Tanaka, A., Kojima, H., Okabe, T., Nagano, T.(2012) J Med Chem 55: 5151-5164
- PubMed: 22540945 
- DOI: 10.1021/jm3001289
- Primary Citation of Related Structures:  
3UMW - PubMed Abstract: 
Serine/threonine kinase PIM1 is an emerging therapeutic target for hematopoietic and prostate cancer therapy. To develop a novel PIM1 inhibitor, we focused on 1, a metabolically labile, nonselective kinase inhibitor discovered in our previous screening study ...